Dynamic Duo: Synergy between Cancer Radiation Therapy and ImmunotherapyYuqi Zhang1 and Manchao Zhang2*
- *Corresponding Author:
- Manchao Zhang
506 TMRF, 420 W.12th Ave
Columbus, OH 43210
Email: [email protected]
Received date: October 09, 2015 Accepted date: October 12, 2015 Published date: October 19, 2015
Citation: Yuqi Zhang, Manchao Zhang (2016) Dynamic Duo: Synergy between Cancer Radiation Therapy and Immunotherapy . Immunother Open Acc 2:107. doi:10.4172/2471-9552.1000107
Copyright: © 2015 Zhang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Immunotherapy is increasingly being applied in conjunction with any of the three commonly accepted treatment modalities of surgery, chemotherapy, and radiation therapy in the treatment of solid and hematological malignancies. Radiation therapy, which can be applied as a monotherapy, has immunostimulatory properties that are specifically augmented when used together with immunotherapy. High-dose irradiation has significant effects on both the targeted tumor and the immune system that are mutually enhancing when applied appropriately. Immunogenic cell death and changes in gene expression in irradiated tumor cells fuel the immune system, allowing for immunemediated killing that leads to improved overall survival. Herein, we discussed the recent advances in radiation therapy and immunotherapy, covering myeloid-derived suppressor cells (MDSCs), radioimmunotherapy, immunocheckpoint inhibition, cancer treatment vaccine, and chimeric antigen receptor (CAR) engineered T cells and NK cells. We put forth our current understanding of the mechanisms behind how immunotherapy and radiation therapy complement each other, and suggest some topics that are worthy of further exploration.